Kyntra Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $24.8M
- Price
- $6.13
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.85%
- Volume
- 16.8K
About
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
Quick stats
Shares outstanding4.0M
Computed float4.0M
Float / shares98.2%
Cash runway (months)19.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000921299
Websitehttps://www.kyntrabio.com
AI Summary
AI-generated1/12
minorneutralboard change
Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
Kyntra Bio appointed Andrew E. Singer, MBA to its Board of Directors as an independent director and Audit Committee member, effective October 1, 2026.
Maykin Ho, Ph.D. stepped down from the Board effective September 30, 2026 after nearly eight years of service.
Singer brings 25+ years of biotech finance and investment banking experience, including CFO of Epizyme and senior roles at Credit Suisse, Wells Fargo, and RBC Capital Markets.